United Bank Viracta Therapeutics, Inc. Transaction History

United Bank

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$0.44 - $1.04 $2,288 - $5,408	5,200 Added 26.0%	25,200 $14,000
Q3 2023 Nov 08, 2023	BUY	$1.03 - $1.58 $10,088 - $15,476	9,795 Added 95.98%	20,000 $20,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $12,858 - $44,697	10,205 New	10,205 $14,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of United Bank, based on Form 13F filings with the SEC.

Stay updated on United Bank with notifications on news.